AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00378209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
Study NCT01754844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7624
Description: Single dose inhaled IMP via a nebulizer
Study NCT01754844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Single dose inhaled Placebo via a nebulizer
Study NCT01423487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 0.5g bid 26 weeks
Study NCT01423487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Starch tablets
Description: 0.5g bid 26 weeks
Study NCT02694237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Model
Description: Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
Study NCT02694237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Knee Anatomy Video
Description: Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
Study NCT02694237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal
Description: Each participant will receive a verbal informed consent discussion without a visual aid.
Study NCT02378363 — intervention group
Intervention type: OTHER
Intervention: Write, draw and interview
Description: Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
Study NCT02268786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preimplantation Genetic Screening by NGS
Description: The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
Study NCT01712854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: budesonide 80 mcg
Study NCT01712854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort
Description: A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
Study NCT04269980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP
Description: MAP
Study NCT00632255 — intervention group
Intervention type: DRUG
Intervention: Imatinib
Description: Conventional therapy with imatinib
Study NCT01977170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib/PRP-T vaccine
Description: Hib liquid vaccine
Study NCT05312528 — intervention group
Intervention type: PROCEDURE
Intervention: endometriosis surgery
Description: Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
Study NCT05312528 — intervention group
Intervention type: PROCEDURE
Intervention: other benign condition surgeries
Description: ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
Study NCT00307736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
Study NCT00307736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
Study NCT00307736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
Study NCT00307736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (EBRT)
Description: Given on days 1-5 and 8-12
Study NCT00423267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
Study NCT00423267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
Study NCT03307395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middel Meningeal Artery Embolization
Description: Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
Study NCT01599611 — intervention group
Intervention type: PROCEDURE
Intervention: Movement assessment battery for children - 2
Description: A standardised test developed to identify developmental difficulties in children.
Study NCT04630561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural Intervention Program
Description: Dynamic warmup program designed to target several areas of physical and mental wellbeing.
Study NCT00198510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Description: 7.5 IU of Vitrase
Study NCT03277755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 25 mg
Description: Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
Study NCT03277755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV 75 mg
Description: Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
Study NCT01739127 — intervention group
Intervention type: DRUG
Intervention: Aripiprazole
Description: To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
Study NCT01739127 — intervention group
Intervention type: DRUG
Intervention: Risperidone/Quetiapine
Description: To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
Study NCT00695305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rilapladib
Description: 250 mg oral dose once daily
Study NCT00695305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00695305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 18F Fluorodeoxylucose (FDG)-PET
Description: FDG-PET
Study NCT04582084 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
Study NCT01619566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
Study NCT04053127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAVANS
Description: Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
Study NCT04053127 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RAVANS
Description: Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
Study NCT03364946 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, observational study
Study NCT01439412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture and standard treatment
Description: This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes.
Study NCT01439412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment in general practice
Description: This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
Study NCT01944111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plication
Description: Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
Study NCT03071939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers
Description: This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services).
Study NCT02713412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
Study NCT02713412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 300ml water
Study NCT05044559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Positive Air Way Group
Description: CPAP between 10 and 12 cmH2O
Study NCT05044559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days.
Study NCT03555292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PiB
Description: 11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
Study NCT02131350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photocoagulation
Description: Photocoagulation include focal/grid laser and/or panretinal photocoagulation
Study NCT02131350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT03308812 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health360x
Description: Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
Study NCT03308812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health360x
Description: Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
Study NCT03308812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coach
Description: Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
Study NCT03519087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Evaluation for Nonarthritic Hip Disease
Description: The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.
Study NCT03519087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture and Movement Training
Description: Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.
Study NCT03519087 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-of-choice
Description: Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
Study NCT01577771 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13 (manufactured by Pfizer)
Description: Prevnar13 administered IM in the antero-lateral thigh
Study NCT01577771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar13 (manufactured by Pfizer)
Description: Prevnar13 administered IM in the antero-lateral thigh
Study NCT04412278 — intervention group
Intervention type: OTHER
Intervention: Online Survey
Description: Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
Study NCT01727037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic intrabullous autologous blood instillation
Study NCT03377101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT03377101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Given IM
Study NCT00733057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline as an add-on drug (200 mg/day)
Study NCT00733057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (200 mg/day)
Study NCT00979849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
Study NCT00979849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation, inhaled
Study NCT00262847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00262847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT00262847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00262847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00262847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00262847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT03377101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT03377101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03377101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03377101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Given PO
Study NCT00262847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03377101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03237507 — intervention group
Intervention type: DRUG
Intervention: S-1
Description: 40-60mg/m\^2 bid, days 1-14, oral，every 3 weeks.
Study NCT00262847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT00262847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IV
Study NCT00262847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00262847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05831761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of analgesic efficacy protocol
Description: Comparison of 4 possible analgesic protocols
Study NCT00871923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva (Erlotinib hydrochloride)
Description: 150 mg by mouth every day beginning Day 1.
Study NCT00871923 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
Study NCT03237507 — intervention group
Intervention type: DRUG
Intervention: oxaliplatin
Description: 100mg/m\^2 days 1，intravenous infusion, every 3 weeks.
Study NCT04077372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious Illness Conversation Guide (SICG)
Description: The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
Study NCT04077372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life (QOL) survey
Description: Quality of life survey by questionnaire (FACT-G) given every three months
Study NCT04077372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) survey
Description: Quality of life survey by questionnaire (FACT-G) given every three months
Study NCT03383757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpO2 Sensor application & blood draw
Description: At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
Study NCT00583791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device closure with the AMPLATZER Muscular VSD Occluder
Description: Device: AMPLATZER Muscular VSD Occluder
Study NCT02433873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isomalto-oligosaccharide
Description: Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
Study NCT04725760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainPort Vision Pro
Description: Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months.
Study NCT02433873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isomalto-oligosaccharide
Description: Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
Study NCT03237507 — intervention group
Intervention type: DEVICE
Intervention: Hyperthermic Intraperitoneal
Description: hyperthermic intraperitoneal chemoperfusion
Study NCT03237507 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: intraperitoneal perfusion
Study NCT02591147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride 38%
Description: Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.